Clearpoint Neuro Ownership
| CLPT Stock | USD 13.67 0.29 2.17% |
Shares in Circulation | First Issued 2011-06-30 | Previous Quarter 27.6 M | Current Value 27.3 M | Avarage Shares Outstanding 11.2 M | Quarterly Volatility 9.8 M |
Clearpoint |
Clearpoint Stock Ownership Analysis
About 33.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.71. Clearpoint Neuro last dividend was issued on the 27th of July 2016. The entity had 1:40 split on the 27th of July 2016. ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 80 people. For more info on Clearpoint Neuro please contact Joseph Burnett at 888 287 9109 or go to https://www.clearpointneuro.com.Besides selling stocks to institutional investors, Clearpoint Neuro also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Clearpoint Neuro's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Clearpoint Neuro's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Clearpoint Neuro Quarterly Liabilities And Stockholders Equity |
|
Clearpoint Neuro Insider Trades History
About 8.0% of Clearpoint Neuro are currently held by insiders. Unlike Clearpoint Neuro's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Clearpoint Neuro's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Clearpoint Neuro's insider trades
Clearpoint Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Clearpoint Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearpoint Neuro backward and forwards among themselves. Clearpoint Neuro's institutional investor refers to the entity that pools money to purchase Clearpoint Neuro's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2024-12-31 | 234.5 K | Jane Street Group Llc | 2024-12-31 | 222.3 K | Taylor Frigon Capital Management Llc | 2024-12-31 | 212.2 K | Conway Capital Management Inc | 2024-12-31 | 161.2 K | Lane Generational Llc | 2024-12-31 | 157.7 K | Parsons Capital Management Inc | 2024-12-31 | 141.6 K | Goldman Sachs Group Inc | 2024-12-31 | 130 K | Legato Capital Management Llc | 2024-12-31 | 122.1 K | State Street Corp | 2024-12-31 | 116.2 K | Vanguard Group Inc | 2024-12-31 | 1.2 M | Susquehanna International Group, Llp | 2024-12-31 | 509.2 K |
Clearpoint Neuro Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearpoint Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearpoint Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearpoint Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Clearpoint Neuro Outstanding Bonds
Clearpoint Neuro issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Clearpoint Neuro uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Clearpoint bonds can be classified according to their maturity, which is the date when Clearpoint Neuro has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Clearpoint Neuro Corporate Filings
F4 | 14th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of January 2025 Other Reports | ViewVerify | |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.